| Preoperative pancreatic duct diameter ≧ 3mm, n (%) | | | | |
|
No
|
10/42 (23.8%)
|
0.777
| | |
|
Yes
|
6/32 (18.8%)
| | | |
| Postoperative pancreatic duct diameter ≧ 3mm, n (%) | | | | |
|
No
|
5/53 (9.4%)
|
< 0.001
|
0.002
|
19.0 (3.022-118.984)
|
|
Yes
|
13/25 (52.0%)
| | | |
|
Postoperative pancreatic parenchymal atrophy, n (%)
| | |
0.001
|
21.2 (3.324-135.697)
|
|
No
|
5/56 (8.9%)
|
< 0.001
| | |
|
Yes
|
13/22 (59.1%)
| | | |
|
Pathology, n (%)
| | | | |
|
Benign
|
12/35 (34.3%)
|
0.057
|
0.253
|
0.4 (0.067-2.038)
|
|
Malignant
|
6/43 (14.0%)
| | | |
|
Type of operation, n (%)
| | | | |
|
Pancreaticoduodenectomy
|
16/73 (21.9%)
|
0.326
| | |
|
Segment resection of pancreas
|
2/5 (40.0%)
| | | |
|
Pancreatic fistula, n (%)
| | | | |
|
No
|
15/61 (24.6%)
|
0.748
| | |
|
Yes
|
3/17 (17.6%)
| | | |
|
Adjuvant therapy, n (%)
| | | | |
|
No
|
13/59 (22.0%)
|
0.002
|
0.087
|
9.3(0.725-118.506)
|
|
Chemotherapy
|
0/12 (0.0%)
| | | |
|
long-acting octreotide
|
5/7 (71.4%)
| | | |
|
I125 radioactive seeds implantation, n (%)
| | | | |
|
No
|
18/74 (24.3%)
|
1.000
| | |
|
Yes
|
0/3 (0.0%)
| | | |
|
Pancreatic duct stent retained > 2 years, n (%)
| | | | |
|
No
|
18/68 (26.5%)
|
0.068
| | |
|
Yes
|
0/10 (0.0%)
| | | |
